Declan Murphy on PSMA Molecules and the Motivation Behind the proPSMA Trial


Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.


So PSMA as a molecule has been of interest for many years really because we know that its overexpressed in aggressive cancer especially castration-resistant prostate cancer. But what we’ve only had in the past 5 or 6 years is imaging agents which are useful to identify this overexpression of PSMA. The real breakthrough came 6 or 7 years ago when some German groups created small molecule ligands that can be used in a PET scanner to identify PSMA in a really quite striking, sensitive and specific manner.

These compounds came out of Germany in 2012/2013 and in Australia we had developed a program already with widespread use of PSMA all around the country really from 2014 onwards. We were beginning to see these striking images and it became very apparent that PSMA PET/CT was an obvious challenger to conventional imaging for staging newly diagnosed prostate cancer and also recurrent prostate cancer and so on. So, in 2017 we set up a prospective randomized trial called the proPSMA trial to compare conventional imaging with PSMA PET/CT for staging newly diagnosed, high-risk or unfavorable intermediate risk prostate cancer.

Related Videos
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.